Advice
Following an abbreviated submission
olmesartan medoxomil/amlodipine as besilate (Sevikar) is accepted for use in NHS Scotland for treatment of essential hypertension in patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
In patients for whom concomitant use of these medicines is appropriate it allows administration of a single tablet at a lower or modestly increased cost compared to the individual components (depending on dose). Angiotensin receptor blockers are an alternative to ACE inhibitors where these are not tolerated. This fixed dose combination is one of many options for the treatment of hypertension, many of which are less expensive.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- olmesartan medoximil / amlodipine besilate (Sevikar)
- SMC ID:
- 574/09
- Indication:
- For treatment of essential hypertension
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 October 2009